| Ytd | 4.05% | |
| 1y | 703.42% |
| Open | 5.21 | Prev Close | 5.30 | Low | 5.01 | High | 5.25 | Mkt Cap | 555.92M |
| Vol | 538.83K | Avg Vol | 1.64M | EPS | -1.09 | P/E | -4.86 | Forward P/E | -0.19 |
| Beta | 0.41 | Short Ratio | 4.52 | Inst. Own | 46.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.58 | 200-d Avg | 5.09 | 1yr Est | 0.87 |
RLMD News
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in s
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-s
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a prim
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock
US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follo
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrationa
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may p
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Alseres Pharmaceuticals (OTCMKTS:ALSE - Ge
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re
US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
On Friday, 209 companies set new 52-week lows.